TWST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Twist Bioscience Corp (TWST) is not a strong buy for a beginner, long-term investor at this moment. While the company shows promising growth potential driven by AI drug discovery and NGS normalization, the financial performance and trading trends suggest caution. The stock is better suited for monitoring rather than immediate investment.
The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 53.401, and moving averages are converging, suggesting no strong directional momentum. Key resistance levels are at 49.475 and 51.67, while support levels are at 42.37 and 40.175.
Analysts have consistently raised price targets, citing growth opportunities in AI-driven drug discovery and NGS normalization. Gross margin has improved significantly YoY, and revenue has grown by 16.89%.
Hedge funds are aggressively selling the stock, with a 634.68% increase in selling activity last quarter. Net income and EPS have declined YoY, and there is no recent news or congress trading data to support a bullish sentiment.
In Q1 2026, revenue increased by 16.89% YoY to $103.7M, and gross margin improved to 52.05%. However, net income dropped by 3.44% to -$30.5M, and EPS declined by 5.66% to -$0.50.
Analysts are bullish, with multiple firms raising price targets to $50-$52 and maintaining Outperform or Buy ratings. They highlight strong growth potential into FY26 driven by AI drug discovery and sector recovery.
